Interestingly, even under conditions of severe B-cell depletion and failed seroconversion, a significantly higher polyfunctional IFNγ + and IL-2 + T-cell response and strong T-cell proliferation capacity were detected compared to controls. Both IgG antibodies recognizing receptor binding domain (RBD) from CoV-2 spike protein and their blocking activity against RBD-hACE2 binding were significantly reduced in aCD20-MS patients, with a seroconversion rate of only 23.8%.

Here, the humoral and cellular responses are analyzed in a group of aCD20-MS patients (n=43) compared to a healthy control cohort (n=34) during the first 6 months after a 2-dose cycle mRNA-based COVID-19 vaccination. MS patients receiving anti-CD20 therapy (aCD20-MS) are considered especially vulnerable due to acquired B-cell depletion and impaired antibody production in response to virus infection and COVID-19 vaccination. Immunocompromised individuals, including multiple sclerosis (MS) patients on certain immunotherapy treatments, are considered susceptible to complications from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and specific vaccination regimens have been recommended for suitable protection.

Tisch Multiple Sclerosis Research Center of New York, New York, NY, United States.

The Center aims to identify the cause of MS, understand disease mechanisms, optimize therapies, and repair the damage caused by MS while offering patients access to the best and most advanced treatments possible.Roberto Alfonso-Dunn, Jerry Lin, Vanessa Kirschner, Joyce Lei, Grant Feuer, Michaela Malin, Jiayuan Liu, Morgan Roche and Saud A. Its integrated relationship with the International Multiple Sclerosis Management Practice (IMSMP) accelerates the pace at which research discoveries translate from lab bench to bedside. The mission of the Tisch Multiple Sclerosis Research Center of New York is to conduct groundbreaking medical research to ensure unparalleled care and positive outcomes for MS patients. The full CNN article can be accessed here.Ībout the Tisch MS Research Center of New York Due to their support, we are able to ensure positive treatment outcomes for patients, as well as in conduct cutting-edge research to find the cause and ultimately, the cure for MS.' 'We’re so grateful to have Jamie-Lynn – as well as our other patients and donors – as advocates of the great work our team is doing. 'We’re proud to have Jamie-Lynn as one of our patients and to support her on her MS journey,' Dr.

The First Year by Saud A. Sadiq MD